Pirfenidone(Esbriet)

The drug was approved for marketing by the U.S. FDA in 2014. Its specific molecular targets remain unclear, but it is known to exert its effects through a multi-pathway anti-fibrotic mechanism. As a prescription medication, it must be used in strict accordance with the instructions of a healthcare professional.

Mechanism of Action

The specific molecular targets of pirfenidone have not been fully elucidated; however, it is known to exert its therapeutic effects through a multi-pathway anti-fibrotic mechanism.

Dosage and Administration

Route and frequency of administration: Pirfenidone is administered orally, once daily.

Dosage adjustments of pirfenidone should be made based on the patient’s individual condition. Specific decisions must be made in consultation with a physician and in strict accordance with medical advice.

Recommended reading: Dosage and Administration of Pirfenidone

Adverse Reactions

Common adverse reactions: Nausea, rash, abdominal pain, etc.

Serious adverse reactions: Hepatic disorders, increased susceptibility to sunlight with subsequent rash, and gastrointestinal disorders.

Reference article: Adverse Reactions of Pirfenidone

Use in Special Populations

Mild to moderate hepatic impairment: Patients with Child-Pugh class A or B should use pirfenidone with caution. Close monitoring for adverse reactions is required, and dosage adjustment or discontinuation of the drug should be considered based on the patient’s condition.

Severe hepatic impairment: The use of pirfenidone is not recommended for patients with Child-Pugh class C, as there are no relevant clinical study data available for this population.

General Precautions

Avoid direct exposure to sunlight, or light emitted by tanning lamps and sunbeds.

Avoid concomitant use of other medications that may cause photosensitivity.

Smoking may reduce the efficacy of pirfenidone.

FDA，2023.02